

**FOR IMMEDIATE RELEASE**

September 29, 2009

KYORIN Co., Ltd.

Eisai Co., Ltd.

**KYORIN and Eisai Sign License Agreement for Development and Marketing of  
Uritos<sup>®</sup> Tablets in China, India, Sri Lanka and ASEAN Countries**

KYORIN Pharmaceutical Co., Ltd. (Headquarters: Tokyo, President and CEO: Keiji Hirai, “KYORIN”), a subsidiary of KYORIN Co., Ltd., and Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito, “Eisai”) announced today the conclusion of a license agreement for Uritos<sup>®</sup> Tablets (generic name: imidafenacin), a therapeutic agent for overactive bladder, discovered and developed by KYORIN. Under the terms of this agreement, KYORIN shall grant Eisai the exclusive rights to develop and market the